Brincidofovir effectively protected large numbers (n = 15) of mice against a lethal ectromelia virus challenge. Buccal swabs were selected as a non-invasive mechanism to sample mice for a biomarker (vDNA) of disease. vDNA in buccal swabs can be detected within the therapeutic window of brincidofovir.